Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 8/20 | 0.62 |
| ▸ | REN | P00797 | 4/20 | 0.62 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | F2 | P00734 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | LTA4H | P09960 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | PEPD | P12955 | 1/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.58 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.58 |
| ▸ | HTR2A | P28223 | 1/20 | 0.58 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.58 |
| ▸ | HRH1 | P35367 | 1/20 | 0.58 |
| ▸ | THPO | P40225 | 1/20 | 0.58 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15854285 | 1.00 | ACE (0.62) | ACERENRAB9AKDM4EF2 | |
| SCHEMBL5742529 | 1.00 | ACE (0.62) | ACERENRAB9AKDM4EF2 | |
| SCHEMBL26213247 | 0.95 | ACE (0.56) | ACERENRAB9AKDM4EF2 | |
| SCHEMBL21246655 | 0.88 | ACE (0.60) | ACERENRAB9AKDM4EF2 | |
| SCHEMBL21246658 | 0.88 | ACE (0.60) | ACERENRAB9AKDM4EF2 | |
| SCHEMBL7380841 | 0.87 | ACE (0.59) | ACERENRAB9AKDM4EF2 | |
| SCHEMBL11581559 | 0.87 | ACE (0.63) | ACERENRAB9AKDM4EF2 | |
| SCHEMBL15791258 | 0.86 | SMN1; SMN2 (0.49) | ACERENRAB9AKDM4EF2 | |
| SCHEMBL26724942 | 0.86 | SMN1; SMN2 (0.49) | ACERENRAB9AKDM4EF2 | |
| SCHEMBL11558594 | 0.85 | ACE (0.66) | ACERENRAB9AKDM4EF2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6531612-B2 | Pyrrolidine-2-carboxylic acid cyano-methyl amide derivatives useful for treating diseases associated with cystein proteases, such as osteoporosis, osteoarthritis, rheumatoid arthritis, tumor metastasis, glomerulonephritis | HOFFMAN-LA ROCHE INC. | 2003-03-11 | — | — | US | claimed |
| US-20010008901-A1 | Nitrile derivatives that inhibit cathepsin K | F. HOFFMANN-LA ROCHE AG (CH) | 2001-07-19 | — | — | US | claimed |
| US-11014941-B2 | Pyrrolopyrimidine derivatives useful as inhibitors of influenza virus replication | COCRYSTAL PHARMA, INC. (US) | 2021-05-25 | — | — | US | disclosed |
| US-20200123177-A1 | PYRROLOPYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF INFLUENZA VIRUS REPLICATION | COCRYSTAL PHARMA, INC. | 2020-04-23 | — | — | US | disclosed |
| US-9388162-B2 | Substituted morphinans and the use thereof | PURDUE PHARMA L.P. (US) | 2016-07-12 | — | — | US | disclosed |
| US-20150175571-A1 | Substituted Morphinans and the Use Thereof | PURDUE PHARMA L.P. | 2015-06-25 | — | — | US | disclosed |
| US-8946255-B2 | Substituted morphinans and the use thereof | PURDUE PHARMA L.P. (US) | 2015-02-03 | — | — | US | disclosed |
| US-20140187573-A1 | Substituted Morphinans and the Use Thereof | PURDUE PHARMA L.P. (US) | 2014-07-03 | — | — | US | disclosed |
| US-20110034434-A1 | PRODRUGS OF FUSED HETEROCYCLIC INHIBITORS OF D-AMINO ACID OXIDASE | SEPRACOR INC. (US) | 2011-02-10 | — | — | US | disclosed |
| US-20100120740-A1 | PRODRUGS OF FUSED HETEROCYCLIC INHIBITORS OF D-AMINO ACID OXIDASE | SEPRACOR INC. (US) | 2010-05-13 | — | — | US | disclosed |
| US-20100120740-A1 | PRODRUGS OF FUSED HETEROCYCLIC INHIBITORS OF D-AMINO ACID OXIDASE | SEPRACOR INC. (US) | 2010-05-13 | — | — | US | disclosed |
| EP-1244621-B1 | NITRILE DERIVATIVES AS CATHEPSIN K INHIBITORS | HOFFMANN LA ROCHE (CH) | 2006-09-13 | — | — | EP | disclosed |
| US-6531612-B2 | Pyrrolidine-2-carboxylic acid cyano-methyl amide derivatives useful for treating diseases associated with cystein proteases, such as osteoporosis, osteoarthritis, rheumatoid arthritis, tumor metastasis, glomerulonephritis | HOFFMAN-LA ROCHE INC. | 2003-03-11 | — | — | US | disclosed |
| US-20010008901-A1 | Nitrile derivatives that inhibit cathepsin K | F. HOFFMANN-LA ROCHE AG (CH) | 2001-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11014941-B2 | Pyrrolopyrimidine derivatives useful as inhibitors of influenza virus replication | ITPA, POLR2H, POLR2E | ACE 17/4885REN 186/4885RAB9A 1737/4885 |
| US-20150175571-A1 | Substituted Morphinans and the Use Thereof | OPRL1, OPRM1, OPRK1 | ACE 3540/4885REN 310/4885RAB9A 1218/4885 |
| US-20100120740-A1 | PRODRUGS OF FUSED HETEROCYCLIC INHIBITORS OF D-AMINO ACID OXIDASE | DDO, DAO, AOC1 | ACE 226/4885REN 988/4885RAB9A 2105/4885 |
| US-20110034434-A1 | PRODRUGS OF FUSED HETEROCYCLIC INHIBITORS OF D-AMINO ACID OXIDASE | DDO, DAO, AOC1 | ACE 226/4885REN 988/4885RAB9A 2105/4885 |
| US-20140187573-A1 | Substituted Morphinans and the Use Thereof | OPRL1, OPRM1, OPRK1 | ACE 3540/4885REN 310/4885RAB9A 1218/4885 |
| US-20200123177-A1 | PYRROLOPYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF INFLUENZA VIRUS REPLICATION | ITPA, POLR2H, POLR2E | ACE 17/4885REN 186/4885RAB9A 1737/4885 |
| US-20010008901-A1 | Nitrile derivatives that inhibit cathepsin K | CTSK, CTSH, CTSS | ACE 42/4885REN 64/4885RAB9A 1522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.